In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against Chinese vitamin A palmitate producers, Indian pharmaceutical firms have initiated a new campaign on March 13. This time, the focus is on China’s manufacturers of vitamin B12 and ceftriaxone sodium, with customs codes 29362610 and 29419055, respectively.
The China Chamber of Commerce of Medicines & Health Products Importers & Exporters (CCCMHPIE) reports that Indian companies Orchid, Lupin, Nector, and Aurobindo have lodged a case with India’s MOFCOM. This case encompasses all major Chinese vitamin B12 producers, reflecting a significant shift in trade dynamics.
Industry insiders reveal that since 2006, Indian companies have ceased domestic production of vitamin B12, opting instead to source it predominantly from China, which accounts for over 70% of the global vitamin B12 supply. Among the prominent Chinese manufacturers are entities under the NCPC umbrella, Victor Pharmaceutical, Kangxin Pharmaceutical, Hualuan Pharmaceutical, Huarong Pharmaceutical—a subsidiary of Shijiazhuang Pharmaceutical Group—as well as Ningxia Duowei Pharmaceutical and Hebei Yuxing.
